Drug Resistance Mechanisms in Mycobacterium Tuberculosis

Mycobacterium tuberculosis has evolved a diverse array of resistance mechanisms that undermine the efficacy of first- and second-line antitubercular agents. Central to this adaptability are chromosomal mutations that modify drug-target interactions, leading to altered binding affinities or catalytic functions. Rifampicin resistance frequently arises from point mutations in the rpoB gene encoding the RNA polymerase β-subunit, whereas isoniazid resistance often involves mutations in katG or inhA and their regulatory regions, affecting drug activation or target expression. Non-target based mechanisms, notably upregulation or structural alteration of efflux pumps such as MmpS5-MmpL5, reduce intracellular drug concentrations and confer cross-resistance between bedaquiline and clofazimine. Genetic epistasis between resistance-associated variants further modulates phenotypic outcomes, complicating susceptibility prediction from genotype alone. Horizontal dissemination of resistant clones and the persistence of pre-existing resistance alleles amplify the global challenge. Advances in whole-genome sequencing now permit quantitative mapping of minimum inhibitory concentrations across multiple drugs, informing both rapid diagnostics and the design of robust pan-tuberculosis regimens that can counter existing resistance reservoirs.

Research from Nature Portfolio

Recent studies have established a quantitative atlas linking specific genomic mutations in M. tuberculosis to graded changes in minimum inhibitory concentration for a broad spectrum of antitubercular agents. By analysing over 15 000 clinical isolates with whole-genome sequencing and high-throughput microtiter assays, researchers identified nearly 500 unique variants that elevate resistance across 13 drugs, alongside mutations that confer hypersensitivity. This comprehensive dataset advances the development of genetic algorithms for resistance prediction, moving beyond binary classification towards nuanced, quantitative diagnostics capable of discerning low-level resistance and guiding individualised therapy.

Drug Resistance Mechanisms in Mycobacterium Tuberculosis publication trend

The graph below shows the total number of articles in drug resistance mechanisms in mycobacterium tuberculosis across all publications each year (not limited to Nature Index journals).

Technical terms

Minimum inhibitory concentration (MIC): The lowest concentration of a drug that inhibits visible growth of a microorganism.

Efflux pump: Membrane proteins that actively export antimicrobial compounds out of bacterial cells, reducing intracellular drug concentration.

Resistance-associated variant (RAV): A genetic mutation that contributes to reduced susceptibility or resistance to an antimicrobial agent.

Epistasis: Interaction between genetic variants whereby the effect of one mutation is influenced by the presence of another.

Whole-genome sequencing: Determination of the complete DNA sequence of an organism’s genome at a single time, enabling comprehensive mutation profiling.

References

1. Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach. Nature Communications (2024).
2. Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis. Genome Medicine (2024).
3. Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline. PLOS ONE (2014).